President Donald Trump's administration may be developing a way to lower prescription drug costs without Congress' involvement, reports The Hill.
Here are three things to know.
1. HHS Secretary Tom Price, MD, held listening sessions with various industry groups and advocates to discuss high drug costs, according to sources who've attended the sessions.
2. Dr. Price and other officials engaged with attendees and asked questions during the sessions, according to the report. Meeting attendees told The Hill they left with the impression the Trump administration was serious about addressing high drug costs.
3. HHS leaders did not share specifics on their drug pricing plans during the sessions. However, they did invite the group to offer feedback once a set of drug cost proposals are developed, one attendee told The Hill.
More articles on supply chain:
Pharma websites prioritize ads over education, physicians say
3 latest FDA approvals
WHO calls for global drug price transparency